Research & KnowledgeEvent: September 1, 2026
Pfizer published a new analysis from the DAN-RSV study evaluating more than 511,000 adults across Denmark and Spain, including new season-two data in adults aged 60 years and older.
Published
Signal category
Research & Knowledge
Quote
“A new analysis from the DAN-RSV study provides important insight into RSV vaccine effectiveness across a diverse population and two seasons.”
— Chris Boshoff, MD, PhD, FMedSci|Pfizer team
Company
- Industry
- Pharmaceutical Manufacturing
- Location
- New York, US
- Company size
- 109,247 employees
We’re celebrating over 175 years of daring scientific innovation—and we’re not done yet. Let’s outdo yesterday. Protect your health at PfizerForAll.com For additional information on our guidelines, please visit http://www.pfizer.com/community-guidelines